A BILL 
To amend the Public Health Service Act to provide for 
the designation of institutions of higher education as 
Centers of Excellence in Cannabis Research, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Developing and Na-
4
tionalizing Key Cannabis Research Act of 2022’’. 
5
23:14 Aug 08, 2022
H8540
2 
•HR 8540 IH
SEC. 2. CANNABIS RESEARCH AT THE DEPARTMENT OF 
1
HEALTH AND HUMAN SERVICES. 
2
(a) NATIONAL CANNABIS RESEARCH AGENDA.—Part 
3
B of title IV of the Public Health Service Act (42 U.S.C. 
4
284 et seq.) is amended by adding at the end the fol-
5
lowing: 
6
‘‘SEC. 409K. NATIONAL CANNABIS RESEARCH AGENDA. 
7
‘‘(a) IN GENERAL.—Not later than 1 year after the 
8
date of enactment of the Developing and Nationalizing 
9
Key Cannabis Research Act of 2022, the Director of NIH, 
10
in collaboration with the Director of the Centers for Dis-
11
ease Control and Prevention, the Commissioner of Food 
12
and Drugs, and the Assistant Secretary for Mental Health 
13
and Substance Use, shall develop a national cannabis re-
14
search agenda that addresses key questions and gaps in 
15
evidence, including with respect to each of the following: 
16
‘‘(1) The safety and efficacy of cannabis in pro-
17
viding therapeutic benefits for certain priority dis-
18
eases or conditions, which may include epilepsy, mul-
19
tiple sclerosis-related spasticity, chemotherapy-in-
20
duced pain and discomfort, using cannabis as an al-
21
ternative to opioid analgesics for acute or chronic 
22
pain, sleep apnea, Tourette syndrome, anxiety, post- 
23
traumatic stress disorder, and any other disease or 
24
condition determined to be appropriate and of im-
25
portance by the Director. 
26
23:14 Aug 08, 2022
H8540
3 
•HR 8540 IH
‘‘(2) The effect of cannabis on at-risk popu-
1
lations, including children, older individuals, and 
2
pregnant or breast-feeding women. 
3
‘‘(3) The nontherapeutic impacts of cannabis 
4
use in the short-term and long-term. 
5
‘‘(4) The long-term effects of cannabis use, in-
6
cluding dose-response relationship and the connec-
7
tion between cannabis use and behavioral health. 
8
‘‘(5) The clinically appropriate dosages and 
9
modes of delivery of cannabis. 
10
‘‘(6) Public safety considerations related to can-
11
nabis, including— 
12
‘‘(A) variation in the potency of cannabis 
13
products; 
14
‘‘(B) youth access to and use of cannabis, 
15
including marketing, packaging, edible formula-
16
tions, and flavor options that target youth; 
17
‘‘(C) risk factors for cannabis misuse; 
18
‘‘(D) impaired driving related to cannabis 
19
use; 
20
‘‘(E) accidental ingestion of cannabis; and 
21
‘‘(F) relative risk of cannabis as compared 
22
to alcohol and tobacco. 
23
‘‘(b) DEFINITION.—In this section, the term ‘can-
24
nabis’ means all parts of the plant Cannabis sativa L., 
25
23:14 Aug 08, 2022
H8540
4 
•HR 8540 IH
whether growing or not; the seeds thereof; the resin ex-
1
tracted from any part of such plant; and every compound, 
2
manufacture, salt, derivative, mixture, or preparation of 
3
such plant, its seeds, or its resin.’’. 
4
(b) SURVEILLANCE ACTIVITIES.—Part A of title III 
5
of the Public Health Service Act (42 U.S.C. 241 et seq.) 
6
is amended by adding at the end the following: 
7
‘‘SEC. 310B. SURVEILLANCE ACTIVITIES ON CANNABIS USE. 
8
‘‘(a) IN GENERAL.—The Secretary, acting through 
9
the Director of the Centers for Disease Control and Pre-
10
vention, in collaboration with the Assistant Secretary for 
11
Mental Health and Substance Use, the Administrator of 
12
the Centers for Medicare & Medicaid Services, and the Di-
13
rector of the Agency for Healthcare Research and Quality, 
14
shall carry out surveillance activities to collect population- 
15
wide data on cannabis use. 
16
‘‘(b) PERMISSIBLE ACTIVITIES.— 
17
‘‘(1) IN GENERAL.—In carrying out activities 
18
under this section, the Secretary may collect, as ap-
19
propriate, with respect to cannabis use— 
20
‘‘(A) data on— 
21
‘‘(i) health outcomes, including bio-
22
logical data; 
23
‘‘(ii) health care utilization, which 
24
shall include hospitalizations and utiliza-
25
23:14 Aug 08, 2022
H8540
5 
•HR 8540 IH
tion of emergency departments related to 
1
consumption of cannabis, including among 
2
youth; 
3
‘‘(iii) demographic factors associated 
4
with cannabis use; 
5
‘‘(iv) the variety of products and deliv-
6
ery modes used; and 
7
‘‘(v) other relevant health information 
8
to improve the understanding of cannabis 
9
use in all age groups and sub-populations; 
10
and 
11
‘‘(B) data through public health surveil-
12
lance systems, surveys, questionnaires, and 
13
databases of health care records, including, as 
14
appropriate, the Behavioral Risk Factor Sur-
15
veillance System, the Youth Risk Behavioral 
16
Surveillance System, the Monitoring the Future 
17
health survey, the National Survey on Drug 
18
Use and Health, or the Healthcare Cost and 
19
Utilization Project (or any successor surveys). 
20
‘‘(2) PRIVACY.—Any data collected under para-
21
graph (1) shall be collected in manner that protects 
22
personal privacy to the extent, at a minimum, that 
23
is required under applicable Federal and State law. 
24
23:14 Aug 08, 2022
H8540
6 
•HR 8540 IH
‘‘(c) DEFINITION.—In this section, the term ‘can-
1
nabis’ means all parts of the plant Cannabis sativa L., 
2
whether growing or not; the seeds thereof; the resin ex-
3
tracted from any part of such plant; and every compound, 
4
manufacture, salt, derivative, mixture, or preparation of 
5
such plant, its seeds, or its resin.’’. 
6
SEC. 3. CENTERS OF EXCELLENCE IN CANNABIS RE-
7
SEARCH. 
8
(a) IN GENERAL.—Part B of title IV of the Public 
9
Health Service Act (42 U.S.C. 284 et seq.), as amended 
10
by section 2, is further amended by adding at the end the 
11
following: 
12
‘‘SEC. 409L. CENTERS OF EXCELLENCE IN CANNABIS RE-
13
SEARCH. 
14
‘‘(a) DESIGNATION.— 
15
‘‘(1) IN GENERAL.—The Director of NIH shall 
16
designate institutions of higher education as Centers 
17
of Excellence in Cannabis Research for the purpose 
18
of interdisciplinary research related to cannabis and 
19
other biomedical, behavioral, and social issues re-
20
lated to cannabis. 
21
‘‘(2) APPLICATION.—To be designated as a 
22
Center of Excellence in Cannabis Research, an insti-
23
tution of higher education shall submit an applica-
24
tion to, and receive approval from, the Director of 
25
23:14 Aug 08, 2022
H8540
7 
•HR 8540 IH
NIH. Such an application shall be submitted in such 
1
manner and contain such information as the Direc-
2
tor of NIH may reasonably require. The Director of 
3
NIH may not approve such an application unless— 
4
‘‘(A) the application contains or is sup-
5
ported by reasonable assurances that— 
6
‘‘(i) the applicant has the experience, 
7
or capability— 
8
‘‘(I) to conduct, through bio-
9
medical, behavioral, social, and related 
10
disciplines, long-term research on can-
11
nabis; and 
12
‘‘(II) to provide coordination of 
13
such research among such disciplines; 
14
‘‘(ii) the applicant has available to it 
15
sufficient personnel and facilities (includ-
16
ing laboratory, reference, storage, security, 
17
and data analysis facilities) to carry out 
18
the research plan required under subpara-
19
graph (B); 
20
‘‘(iii) the applicant has the capacity to 
21
conduct academic courses and train stu-
22
dents and professionals on appropriate re-
23
search and knowledge of cannabis; and 
24
23:14 Aug 08, 2022
H8540
8 
•HR 8540 IH
‘‘(iv) the applicant will secure State 
1
funds for research related to cannabis to 
2
complement any Federal funds for such re-
3
search under this section; and 
4
‘‘(B) the application contains a detailed 5- 
5
year plan for research relating to cannabis. 
6
‘‘(3) PRIORITY.—In selecting institutions of 
7
higher education for designation as Centers of Ex-
8
cellence in Cannabis Research, the Director of NIH 
9
shall give priority to such institutions that have 
10
proven track records in medicinal cannabis research. 
11
‘‘(4) GEOGRAPHIC REPRESENTATION.—The Di-
12
rector of NIH shall, to the extent practicable, ensure 
13
geographic representation across the United States 
14
in designating institutions of higher education as 
15
Centers of Excellence in Cannabis Research. 
16
‘‘(5) TERM
OF
DESIGNATION.—A designation 
17
under this section shall be for a period of 5 years, 
18
so long as the institution of higher education con-
19
tinues to meet the requirements of paragraph (2). 
20
An institution of higher education may reapply in 
21
accordance with the requirements of paragraph (2) 
22
for a subsequent designation under this section. 
23
‘‘(b) CANNABIS RESEARCH.— 
24
23:14 Aug 08, 2022
H8540
9 
•HR 8540 IH
‘‘(1) 
GRANTS
OR
COOPERATIVE
AGREE-
1
MENTS.— 
2
‘‘(A) IN GENERAL.—The Director of NIH 
3
may make grants to, or enter into cooperative 
4
agreements with, 10 Centers that have been 
5
designated under this section to expand the cur-
6
rent and ongoing interdisciplinary research and 
7
clinical trials relating to cannabis research. 
8
‘‘(B) 
AUTHORIZATION
OF
APPROPRIA-
9
TIONS.—To carry out this paragraph, there is 
10
authorized to be appropriated $50,000,000 for 
11
each of fiscal years 2024 through 2028. 
12
‘‘(2) RESEARCH
RESULTS.—The Director of 
13
NIH shall promptly disseminate research results 
14
under this subsection to relevant governmental, aca-
15
demic, and research entities. 
16
‘‘(c) DEFINITIONS.—In this section: 
17
‘‘(1) The term ‘cannabis’ means all parts of the 
18
plant Cannabis sativa L., whether growing or not; 
19
the seeds thereof; the resin extracted from any part 
20
of such plant; and every compound, manufacture, 
21
salt, derivative, mixture, or preparation of such 
22
plant, its seeds, or its resin. 
23
23:14 Aug 08, 2022
H8540
10 
•HR 8540 IH
‘‘(2) The term ‘institution of higher education’ 
1
has the meaning given the term in section 101(a) of 
2
the Higher Education Act of 1965.’’. 
3
(b) REGISTRATION REQUIREMENTS.—Section 303 of 
4
the Controlled Substances Act (21 U.S.C. 823) is amend-
5
ed by adding at the end the following: 
6
‘‘(l) REGISTRATION OF PRACTITIONERS AT CENTERS 
7
OF EXCELLENCE IN CANNABIS RESEARCH.— 
8
‘‘(1) IN GENERAL.—The Attorney General shall 
9
register under subsection (f) practitioners at Centers 
10
of Excellence in Cannabis Research designated 
11
under section 409L of the Public Health Service Act 
12
to conduct research with marijuana. 
13
‘‘(2) TESTING OF CONSTITUENTS.—To the ex-
14
tent a Center of Excellence in Cannabis Research in 
15
a State tests marijuana products that are lawfully 
16
available for such testing in such State for 
17
cannabinoid and noncannabinoid constituents, no 
18
sanction under this title shall apply to such testing, 
19
including the acquisition of such products for such 
20
testing. 
21
‘‘(3) USE
OF
MARIJUANA
PRODUCTS
UNDER 
22
STATE
LAW.—No sanction under this title shall 
23
apply to the acquisition or use of marijuana prod-
24
ucts for a clinical trial or other research to the ex-
25
23:14 Aug 08, 2022
H8540
11 
•HR 8540 IH
tent such clinical trial or other research is con-
1
ducted— 
2
‘‘(A) to further the goals of the national 
3
cannabis research agenda under section 409K; 
4
and 
5
‘‘(B) at a Center of Excellence in Cannabis 
6
Research in a State using marijuana products 
7
that are lawfully available for such purpose 
8
under laws of the State. 
9
‘‘(4) DEFINITION.—In this subsection, the term 
10
‘Center of Excellence in Cannabis Research’ means 
11
a Center of Excellence in Cannabis Research for 
12
which a designation is in effect under section 
13
409L(a) of the Public Health Service Act.’’. 
14
Æ 
23:14 Aug 08, 2022
H8540
